Allarity Therapeutics (ALLR) Operating Expenses (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Operating Expenses came in at $2.7 million in Q1 2026, down 10.64% YoY from $3.0 million in Q1 2025, and down 16.21% on a QoQ basis from $3.2 million in Q4 2025.
Allarity Therapeutics (ALLR) Operating Expenses (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Operating Expenses data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Operating Expenses fell 10.64% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.6 million (down 51.6% YoY) and the FY2025 annual result came in at $12.9 million, down 52.55% from the prior year.
- Operating Expenses eased to $2.7 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $18.3 million in Q1 2022 to a low of $2.5 million in Q3 2025.
- A 5-year average of $5.6 million and a median of $4.2 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses jumped 643.66% — and 2023, when it plunged 79.97%.
- Tracing ALLR's Operating Expenses over 5 years: stood at $6.8 million in 2022, then dropped by 27.72% to $4.9 million in 2023, then jumped by 49.97% to $7.3 million in 2024, then slumped by 55.75% to $3.2 million in 2025, then declined by 16.21% to $2.7 million in 2026.
- The last three Operating Expenses figures came in at $2.7 million (Q1 2026), $3.2 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 541.02 Mn |
| 10 | Allarity Therapeutics | 22.59 Mn | 22.59 Mn | - | 2.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.71 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | 2.52 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 3.04 Mn |
| Dec 31, 2024 | 7.32 Mn |
| Sep 30, 2024 | 12.31 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 4.24 Mn |
| Dec 31, 2023 | 4.88 Mn |
| Sep 30, 2023 | 4.43 Mn |
| Jun 30, 2023 | 4.16 Mn |
| Mar 31, 2023 | 3.67 Mn |
| Dec 31, 2022 | 6.75 Mn |
| Sep 30, 2022 | 4.56 Mn |
| Jun 30, 2022 | 4.84 Mn |
| Mar 31, 2022 | 18.31 Mn |
| Dec 31, 2021 | 15.74 Mn |
| Sep 30, 2021 | 3.97 Mn |
| Jun 30, 2021 | 4.38 Mn |